Cargando…
Expanded Access and Right To Try Requests: The Community Oncologist's Experience
PURPOSE: For patients with cancer who have exhausted approved treatment options and for whom appropriate clinical trials are not available, access to investigational drugs through the US Food and Drug Administration's Expanded Access (EA) program has been an alternative since the program's...
Autores principales: | Zettler, Marjorie E., Jeune-Smith, Yolaine, Feinberg, Bruce A., Phillips, Ajeet, Gajra, Eli G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600511/ https://www.ncbi.nlm.nih.gov/pubmed/33886355 http://dx.doi.org/10.1200/OP.20.00569 |
Ejemplares similares
-
Impact of social determinants of health on cancer care: a survey of community oncologists
por: Zettler, Marjorie E, et al.
Publicado: (2021) -
A survey of pediatric hematologists/oncologists’ perspectives on
single patient Expanded Access and Right to Try
por: Chapman, Carolyn Riley, et al.
Publicado: (2021) -
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
por: Gajra, Ajeet, et al.
Publicado: (2022) -
Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials
por: Feinberg, Bruce A., et al.
Publicado: (2021) -
Impact of Augmented Intelligence on Utilization of Palliative Care Services in a Real-World Oncology Setting
por: Gajra, Ajeet, et al.
Publicado: (2022)